ArticleJournal of Cancer2016
HOXC9 Induces Phenotypic Switching between Proliferation and Invasion in Breast Cancer Cells.
Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- HOXC9 promotes cell proliferation and suppresses mitochondria-dependent apoptosis through the AKT/mTOR pathway in esophageal squamous cell carcinoma.Molecular and cellular biochemistry · 2026Article
- LAMTOR5 drives glioblastoma progression via activation of the HOXC9/YTHDF2 positive feedback loop.The Journal of biological chemistry · 2026Article
- HOXC9 accelerates esophageal squamous cell carcinoma progression via OTUD1-FABP5-mediated lipid metabolic reprogramming.Cell death & disease · 2026Article
- Sex-specific nonlinear DNA methylation aging trajectories reveal biomarkers of cancer risk and inflammation.Genome biology · 2026Article
- HOXC-AS1 and EZH2 interaction increase HOXC9 expression and promote the malignant transformation of oral leukoplakia.Journal of Cancer · 2025Article
- Integrating Bulk and Single-Cell RNA Sequencing Data Reveals the Prognostic Significance of HOXC9-Related Immune Gene Signatures in Hepatocellular Carcinoma.OncoTargets and therapy · 2025Article
- Recent advancements in understanding of biological role of homeobox C9 in human cancers.World journal of clinical oncology · 2024Review
- Article
- Identification of a potential bioinformatics-based biomarker in keloids and its correlation with immune infiltration.European journal of medical research · 2023Article
- Systematic analyses of GWAS summary statistics from UK Biobank identified novel susceptibility loci and genes for upper gastrointestinal diseases.Journal of human genetics · 2023Article
- Tumor-matrix interaction induces phenotypic switching in liver cancer cells.Hepatology international · 2022Article
- Cell-type-specific epigenomic variations associated withNAR genomics and bioinformatics · 2022Article
- Recent Multiomics Approaches in Endometrial Cancer.International journal of molecular sciences · 2022Review
- Upregulation of HOXC9 generates interferon-gamma resistance in gastric cancer by inhibiting the DAPK1/RIG1/STAT1 axis.Cancer science · 2021Article
- Prognostic and clinical significance of HOXC9 and HOXD10 in papillary thyroid cancer.Translational cancer research · 2021Article
- HOXC9 overexpression is associated with gastric cancer progression and a prognostic marker for poor survival in gastric cancer patients.International journal of clinical oncology · 2020Article
- Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.Archives of dermatological research · 2020Article
- Cancer and Microenvironment Plasticity: Double-Edged Swords in Metastasis.Trends in pharmacological sciences · 2019Review
- Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers.PloS one · 2019Article
- Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HOX genes encode a family of transcriptional regulators that are involved in pattern formation and organogenesis during embryo development. In addition, these genes play important roles in adult tissues and some of the dysregulated HOX genes are associated with cancer development and metastasis. Like many other HOX genes, HOXC9 is aberrantly expressed in certain breast cancer cell lines and tissues; however, its specific functions in breast cancer progression were not investigated. In the present study, we demonstrated that HOXC9 overexpression in breast cancer cell lines such as MDA-MB-231 and MCF7 increased the invasiveness but reduced the proliferation of cells, resembling a phenotype switch from a proliferative to an invasive state. Furthermore, the reciprocal result was detected in MCF7 and BT474 cells when the expression level of HOXC9 was reduced with siRNA. The clinical impact of HOXC9 in breast cancer was interpreted from the survival analysis data, in which high HOXC9 expression led to considerably poorer disease-free survival and distant metastasis-free survival, especially in lymph node-positive patients. Together, the prognostic relevance of HOXC9 and the HOXC9-derived phenotypic switch between proliferative and invasive states in the breast cancer cell lines suggest that HOXC9 could be a prognostic marker in breast cancer patients with lymph node metastasis and a target for therapeutic intervention in malignant breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.